Israel Active

Israel’s Alpha Tau (see previously) has used its Alpha DaRT technology to treat the first Israeli patient with advanced inoperable pancreatic cancer in a clinical trial at Hadassah Medical Center in Jerusalem.

Researchers at Israel’s Technion have developed an AI system that identified 77 approved cancer nano-therapies that can chemically self-assemble in nearly 2,000 combinations to be far more effective, with less side-effects. They proved their system, combining bortezomib-cabozantinib to treat head/neck cancer.

GranaGard Nano Omega 5, made by Israel’s Granalix Biotechnologies, is now available in Israel and online. The nano-engineered high antioxidant supplement from pomegranate oil improves cognitive function in Multiple Sclerosis patients and will be tested on dementia patients.

Israel’s Limaca Medical (see previously) has received US FDA approval for its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device. The device automatically obtains biopsies, for diagnosis of pancreatic cancer and other cancers, quicker and safer than current products.

Israel’s Techsomed (see previously) has received US FDA approval for its Ablation Treatment Planning and Confirmation Software. VisAble.IO helps guide surgeons using ablation therapy (extreme heat or cold) to destroy tumors.

Israel’s Elgan Pharma (see previously) has been awarded a 2.36 million euros grant by the European Innovation Council. It will support a Phase III study of its ELGN-GL oral insulin-based formulation that helps the development of a preemie’s gastrointestinal (GI) system.

Israel’s Nasus Pharma (see previously) has reported positive results from its latest clinical study of its FMXIN002 intranasal Epinephrine powder spray device. It provides a safe and effective rescue for the emergency treatment of life-threatening allergic reactions.

Israel’s UroGen Pharma (see previously) has published positive results from two clinical trials of bladder cancer treatment UGN-102. The therapy can benefit some 80,000 patients. Trial success (65%) was similar to patients who had surgery but with a 55% less re-occurrence rate.

A woman with Stevens-Johnson Syndrome (SJS) was saved by doctors at Soroka-University Medical Center in Beersheba. The genetic disease progresses into toxic epidermal necrolysis – a life threatening condition causing 30% of the skin to peel off.

Israel’s Pharma Two B (see previously) is presenting the full results of its Phase 3 trial of its once-a-day injection of its P2B001 treatment for Parkinson’s disease. P2B001 combines low-dose pramipexole with low-dose rasagiline. It relieves PD symptoms with few side effects.